Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

Background: Palmoplantar psoriasis can severely impact patient quality of life. Despite the influx of many new medications, it remains one of the most challenging psoriasis phenotypes to treat. Case Description: Herein, we present a case series of 7 patients with hyperkeratotic palmoplantar psoriasis refractory to systemic therapy who were successfully treated with tofacitinib, a Janus kinase (JAK) 1/3 inhibitor. Conclusions: Tofacitinib may be an effective therapy for the management of recalcitrant palmoplantar psoriasis. The efficacy of tofacitinib for the treatment of palmoplantar psoriasis might clarify the dependence on this subtype of psoriasis on specific cytokines that signal through JAK 1/3.